@ARTICLE{
author={Siefker-Radtke Arlene O,Lugowska Iwona,Tupikowski Krzysztof,Andric Zoran G,Rezazadeh-Kalebasty A,Curigliano Giuseppe,Vaena Daniel A,Vogl FD,Currie Graeme,Abella S,Kelly William Kevin},
year={2019},
title={Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22},
journal={ANNALS OF ONCOLOGY},
volume={30},
number={},
pages={365-365},
document_type={Meeting Abstract},
}